McLeod DG - Search Results

1

Risk factors for perineal seeding of prostate cancer after needle biopsy.

Moul JW, Miles BJ, Skoog SJ, McLeod DG. Moul JW, et al. Among authors: mcleod dg. J Urol. 1989 Jul;142(1):86-8. doi: 10.1016/s0022-5347(17)38668-8. J Urol. 1989. PMID: 2733112

2

Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.

Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW. Gancarczyk KJ, et al. Among authors: mcleod dg. Urology. 2003 Mar;61(3):589-95. doi: 10.1016/s0090-4295(02)02287-2. Urology. 2003. PMID: 12639653

3

Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors.

Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG. Fernandez EB, et al. Among authors: mcleod dg. Urology. 1994 Oct;44(4):548-52. doi: 10.1016/s0090-4295(94)80056-1. Urology. 1994. PMID: 7941194 Review.

4

Efficacy of radiographic chest imaging in patients with testicular cancer.

Fernandez EB, Colon E, McLeod DG, Moul JW. Fernandez EB, et al. Among authors: mcleod dg. Urology. 1994 Aug;44(2):243-8; discussion 248-9. doi: 10.1016/s0090-4295(94)80139-8. Urology. 1994. PMID: 8048200

5

Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man.

Heidenberg HB, Moul JW, Mostofi FK, McLeod DG. Heidenberg HB, et al. Among authors: mcleod dg. J Urol. 1994 Sep;152(3):966-7. doi: 10.1016/s0022-5347(17)32626-5. J Urol. 1994. PMID: 8051769

6

Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.

Moul JW, Douglas TH, McCarthy WF, McLeod DG. Moul JW, et al. Among authors: mcleod dg. J Urol. 1996 May;155(5):1667-73. J Urol. 1996. PMID: 8627850 Clinical Trial.

7

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Bettencourt MC, et al. Among authors: mcleod dg. J Urol. 1996 Sep;156(3):1064-8. J Urol. 1996. PMID: 8709308

8

Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.

Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Bauer JJ, et al. Among authors: mcleod dg. J Urol. 1996 Oct;156(4):1511-6. J Urol. 1996. PMID: 8808919

9

The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?

Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. Heidenberg HB, et al. Among authors: mcleod dg. Urology. 1996 Dec;48(6):971-9. doi: 10.1016/s0090-4295(96)00365-2. Urology. 1996. PMID: 8973691 Review. No abstract available.

10

Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen.

Morgan TO, McLeod DG, Leifer ES, Murphy GP, Moul JW. Morgan TO, et al. Among authors: mcleod dg. Urology. 1996 Dec;48(6A Suppl):76-80. doi: 10.1016/s0090-4295(96)00615-2. Urology. 1996. PMID: 8973705

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

277 results

Search Page

Filters